← back to search

Shengjie Cui

Northwell Health · US
Area of research
Complementary and Manual Therapy · Rheumatology
Research interest
Research interests include Temporomandibular Joint Disorders, Osteoarthritis Treatment and Mechanisms, Orthodontics and Dentofacial Orthopedics, and Bone Tissue Engineering Materials.
h-index
23
citations
1,577
works
70
NIH funding
primary concept
email

Recent publications

Necessity And Indications For Vertical Control In Skeletal Class 2
International Dental Journal 2025cited by 0position: lastdoi
Quantitative evaluation of vertical control in orthodontic camouflage treatment for skeletal class II with hyperdivergent facial type
Head & Face Medicine 2024cited by 11position: middledoi
Force-Induced Autophagy in Periodontal Ligament Stem Cells Modulates M1 Macrophage Polarization via AKT Signaling
Frontiers in Cell and Developmental Biology 2021cited by 51position: middledoi
228MO PALOMA-4: Primary results from a phase III trial of palbociclib (PAL) + letrozole (LET) vs placebo (PBO) + LET in Asian postmenopausal women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative (ER+/HER2–) advanced breast cancer (ABC)
Annals of Oncology 2021cited by 10position: middledoi
Mechanical load-induced H2S production by periodontal ligament stem cells activates M1 macrophages to promote bone remodeling and tooth movement via STAT1
Stem Cell Research & Therapy 2020cited by 94position: middledoi
Efficacy of utidelone plus capecitabine versus capecitabine for heavily pretreated, anthracycline- and taxane-refractory metastatic breast cancer: final analysis of overall survival in a phase III randomised controlled trial
Annals of Oncology 2020cited by 47position: middledoi
Abstract P6-17-17: Pertuzumab, trastuzumab, and docetaxel for HER2-positive early or locally advanced breast cancer in the neoadjuvant setting: Efficacy and safety analysis of a randomized phase III study in Asian patients (PEONY)
Cancer Research 2019cited by 3position: middledoi
Phase III trial of chidamide, a subtype-selective histone deacetylase (HDAC) inhibitor, in combination with exemestane in patients with hormone receptor-positive advanced breast cancer
Annals of Oncology 2018cited by 7position: middledoi
Signal characteristics of normal adult bone marrow in whole-body diffusion-weighted imaging
Acta Radiologica 2016cited by 16position: lastdoi
Characterizing the Blood Oxygen Level-Dependent Fluctuations in Musculoskeletal Tumours Using Functional Magnetic Resonance Imaging
Scientific Reports 2016cited by 6position: middledoi
Abstract P4-12-17: Pathological responses and heart safety analysis of trastuzumab and paclitaxel based regimen plus carboplatin or epirubicin as neoadjuvant therapy in clinical stage II-III, HER2-positive breast cancer patients: A phase 2, open-label, multicentre, randomised trial
Cancer Research 2013cited by 0position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Cuizhi Geng · Hebei Medical University3 papers (2013–2021)Yanheng Zhou · National Clinical Research Center for Digestive Diseases3 papers (2020–2024) · 2 papers (2024–2025)Tao Sun · Wuhan University2 papers (2018–2021)Jieni Zhang · The First Affiliated Hospital, Sun Yat-sen University2 papers (2024–2025)Yan Liu · King University2 papers (2020–2021)Da Pang · First People's Hospital of Foshan2 papers (2013–2019)Zhimin Shao · Shanghai Medical College of Fudan University2 papers (2013–2019)Danqing He · New York University2 papers (2020–2021)Huajie Yu · King University2 papers (2020–2021)S. Wang · Hebei Medical University2 papers (2018–2021)Jianling Cui · Hebei Medical University2 papers (2016–2016)W. Li · Ningbo University2 papers (2018–2021)Q. Zhang · China Academy of Space Technology2 papers (2018–2021)Nan Jiang · University of Alabama at Birmingham2 papers (2020–2021)Hong Yu · Harvard University1 papers (2016–2016)Shi-Lei Wang · Shandong University1 papers (2016–2016)Yi Wang · Sun Yat-sen University Cancer Center1 papers (2019–2019)Ying Cheng · Changzhi University1 papers (2021–2021)Xiaowen Wu · Shanxi Medical University1 papers (2021–2021)